NCT01057277

RAD001, Cisplatin and Concurrent Radiation for Locally Advanced, Inoperable Head and Neck Cancer

BrUOG-H&N-229-RAD001, Cisplatin and Concurrent Radiation for Locally Advanced, Inoperable Head and Neck Cancer: A PHASE I STUDY- Novartis CRAD001CUS134T

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 3 (actual)
• Sponsor: howard safran · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine if RAD001, to a maximum dose of 10 mg/day, can be safely administered with cisplatin, and concurrent radiotherapy, for patients with locally advanced, inoperable, squamous cell carcinoma of the head and neck.

Detailed description

To perform a phase I study of RAD001, to a maximum dose of 10 mg/day, with cisplatin, and concurrent radiotherapy, for patients with locally advanced, inoperable, squamous cell carcinoma of the head and neck

Conditions

• Head and Neck Cancer

Interventions

Type	Name	Description
DRUG	RAD001(Afinitor)	Rad001 in combination withCisplatin and Concurrent RT

Timeline

• Start date: 2009-12-01
• Primary completion: 2011-05-01
• Completion: 2011-06-01
• First posted: 2010-01-27
• Last updated: 2020-02-17
• Results posted: 2015-08-04

Locations

1 site across 1 country: United States